Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

Dr. Kenneth Anderson

Home/Tag:Dr. Kenneth Anderson
28 07, 2013

Myeloma research team at Dana-Farber among the world’s best!

Tags: , , , , , , |2 Comments

Melanie Graham from Dana-Farber contacted me last week to let me know about an article featuring Dr. Anderson, Dr. Richardson and their colleague, Dr. Nikhil Munshi.  Myeloma geeks like me know that Ken Anderson and Paul Richardson are two of the most renowned myeloma specialists in the world.  If they made sets of baseball cards

30 01, 2013

Myeloma education key to becoming a long-lived survivor!

Tags: , , , , , |7 Comments

I had the opportunity to participate in and listen to two different educational programs this week.  Monday I volunteered to host and speak to a group  fellow Moffitt Cancer Center patients, caregivers and family members.  Over 100 attended a three part educational event. Neurosurgeon Dr. Nam Tran spoke to the group about bone disease treatment

10 11, 2012

Dr. Ken Anderson discusses potential of combination therapies

Tags: , , , , , |9 Comments

Enough about me!  Here's an excerpt I saved from earlier this week on OncLive.com, featuring an interview with Dana-Farber's Dr. Ken Anderson: Overcoming Genetic Transformation in Multiple Myeloma Bonnie Gillis - OriginallyPublished Online: Tuesday, November 6, 2012 The goal in treating newly diagnosed multiple myeloma is to achieve deep remission and prevent relapse, Kenneth C.

12 09, 2012

Early lab results look promising for patients refractory to Velcade

Tags: , , , |5 Comments

Our old friend, Dr. Kenneth Anderson, is at it again!  Check-out excerpts from Dana Farber's website about an experimental anti-myeloma molecule, P5091: Molecule shows effectiveness against drug-resistant myeloma Posted On: September 10, 2012 BOSTON––A molecule that targets the cell's machinery for breaking down unneeded proteins can kill multiple myeloma cancer cells resistant to the frontline

17 02, 2010

Multiple Myeloma Drug, Vorinostat, Phase II Trial To Move Forward

Tags: , , , , |0 Comments

Here is a press release, posted on the Drug Discovery & Development Website from Merck Pharmaceuticals about the new, experimental multiple myeloma drug, Vorinostat:Board Recommends Continuation of Phase IIb Study of VorinostatDrug Discovery & Development - February 15, 2010Merck & Co., Inc. announced that an independent Data Safety and Monitoring Board recommended the continuation of

21 12, 2009

Details About New Anti-Myeloma Drug, Perifosine

Tags: , , , , |0 Comments

Here is a clinical summary about the new myeloma drug I wrote about last night, perifosine, from a Website named "drugdevelopment-technology.com:"KRX-0401 (perifosine) is a potential oral anti-cancer agent that suppresses the pathways associated with the programmed growth, death, differentiation and survival of cells. Developed by Keryx, the drug is most effective in modulating Akt, as

21 12, 2009

Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma

Tags: , , , , |0 Comments

Here is info about a newly organized Phase 3 study combining perifosine with Velcade:NEW YORK, Dec 16, 2009 /PRNewswire-FirstCall via COMTEX/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today the initiation of a Phase 3 registration clinical trial for KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor, in relapsed / refractory multiple myeloma patients. The trial,